Congress funds Down syndrome research program with stakeholder oversight
S. 1838 — DeOndra Dixon INCLUDE Project Act of 2025 · Filed by John Hickenlooper (D-CO) · 9 cosponsors · Introduced May 21, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes the INCLUDE Project, a federally funded research program at the National Institutes of Health (NIH) focused on Down syndrome. It directs the NIH Director to conduct and coordinate research on Down syndrome across the lifespan, including studies of co-occurring conditions (like Alzheimer's disease and autoimmunity), clinical trials inclusive of people with Down syndrome, and interventions to improve quality of life. The bill requires biennial reports to Congress on research activities and outcomes.
Why we flagged it
The bill's core mechanism is a direct appropriation and mandate for NIH-led research on Down syndrome and related conditions. It is a straightforward public-health research program with no deregulatory, tax, or liability-shield components.
What the text implies
- The bill's requirement for biennial congressional reporting creates a durable accountability mechanism, ensuring sustained legislative oversight of research priorities and outcomes.
- Mandating coordination across NIH institutes and centers may reduce research fragmentation and improve resource allocation, but implementation depends on NIH administrative capacity and budget appropriations.
The full analysis lists 3 implications of this text.
Who stands to gain
National Institutes of Health (research funding recipient); Academic medical centers and research institutions (grant recipients); Pharmaceutical and biotech companies (potential beneficiaries of research findings and expanded clin